Aidan T. Pezacki

Aidan T. Pezacki

Auto-generated profile, based on publicly available information

Aidan T. Pezacki

Department of Chemistry, Princeton University, Princeton, NJ, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2024 in Chemical Reviews
Verified
Journal Article
Closed access
KGKarandeep Grover
Karandeep Grover
AKAlla Koblova
Alla Koblova
APAidan T. Pezacki
Aidan T. Pezacki
CCChristopher J. Chang
Christopher J. Chang
Elizabeth NewElizabeth New
Elizabeth New

17 October 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
APAidan T. Pezacki
Aidan T. Pezacki
CMCarson D. Matier
Carson D. Matier
XGXingxing Gu
Xingxing Gu
EKEric Kummelstedt
Eric Kummelstedt
SBSarah E. Bond
Sarah E. Bond
CCChristopher J. Chang
Christopher J. Chang
Copper is an essential metal nutrient for life that often relies on redox cycling between Cu(I) and Cu(II) oxidation states to fulfill its physiological roles, but alterations in cellular redox status can lead to imbalances in copper homeostasis that contribute to cancer and other metalloplasias with metal-dependent disease vulnerabilities. Copper-responsive fluorescent probes offer powerful tools to study labile copper pools, but most of these reagents target Cu(I), with limited methods for monitoring Cu(II) owing to its potent fluorescence quenching properties. Here, we report an activity-based sensing strategy for turn-on, oxidation state-specific detection of Cu(II) through metal-directed acyl imidazole chemistry. Cu(II) binding to a metal and oxidation state-specific receptor that accommodates the harder Lewis acidity of Cu(II) relative to Cu(I) activates the pendant dye for reaction with proximal biological nucleophiles and concomitant metal ion release, thus avoiding fluorescence quenching. Copper-directed acyl imidazole 649 for Cu(II) (CD649.2) provides foundational information on the existence and regulation of labile Cu(II) pools, including identifying divalent metal transporter 1 (DMT1) as a Cu(II) importer, labile Cu(II) increases in response to oxidative stress induced by depleting total glutathione levels, and reciprocal increases in labile Cu(II) accompanied by decreases in labile Cu(I) induced by oncogenic mutations that promote oxidative stress.

25 November 2024 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
YJYishu Jiang
Yishu Jiang
EKElsy El Khoury
Elsy El Khoury
APAidan T. Pezacki
Aidan T. Pezacki
NQNaixin Qian
Naixin Qian
MOMiku Oi
Miku Oi
CCChristopher J. Chang
Christopher J. Chang

15 January 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
MMMarco S. Messina
Marco S. Messina
LTLaura Torrente
Laura Torrente
APAidan T. Pezacki
Aidan T. Pezacki
HHHanna I. Humpel
Hanna I. Humpel
ELErin L. Li
Erin L. Li
CCChristopher J. Chang
Christopher J. Chang
Copper is an essential nutrient for sustaining vital cellular processes spanning respiration, metabolism, and proliferation. However, loss of copper homeostasis, particularly misregulation of loosely bound copper ions which are defined as the labile copper pool, occurs in major diseases such as cancer, where tumor growth and metastasis have a heightened requirement for this metal. To help decipher the role of copper in the etiology of cancer, we report a histochemical activity-based sensing approach that enables systematic, high-throughput profiling of labile copper status across many cell lines in parallel. Coppermycin-1 reacts selectively with Cu(I) to release puromycin, which is then incorporated into nascent peptides during protein translation, thus leaving a permanent and dose-dependent marker for labile copper that can be visualized with standard immunofluorescence assays. We showcase the utility of this platform for screening labile Cu(I) pools across the National Cancer Institute’s 60 (NCI-60) human tumor cell line panel, identifying cell types with elevated basal levels of labile copper. Moreover, we use Coppermycin-1 to show that lung cancer cells with heightened activation of nuclear factor-erythroid 2-related factor 2 (NRF2) possess lower resting labile Cu(I) levels and, as a result, have reduced viability when treated with a copper chelator. This work establishes that methods for labile copper detection can be used to assess cuproplasia, an emerging form of copper-dependent cell growth and proliferation, providing a starting point for broader investigations into the roles of transition metal signaling in biology and medicine.

5 July 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
APAidan T. Pezacki
Aidan T. Pezacki
RGRyan L. Gonciarz
Ryan L. Gonciarz
TOToshitaka Okamura
Toshitaka Okamura
CMCarson D. Matier
Carson D. Matier
LTLaura Torrente
Laura Torrente
CCChristopher J. Chang
Christopher J. Chang
Iron is an essential element for life owing to its ability to participate in a diverse array of oxidation–reduction reactions. However, misregulation of iron-dependent redox cycling can also produce oxidative stress, contributing to cell growth, proliferation, and death pathways underlying aging, cancer, neurodegeneration, and metabolic diseases. Fluorescent probes that selectively monitor loosely bound Fe(II) ions, termed the labile iron pool, are potentially powerful tools for studies of this metal nutrient; however, the dynamic spatiotemporal nature and potent fluorescence quenching capacity of these bioavailable metal stores pose challenges for their detection. Here, we report a tandem activity-based sensing and labeling strategy that enables imaging of labile iron pools in live cells through enhancement in cellular retention. Iron green-1 fluoromethyl (IG1-FM) reacts selectively with Fe(II) using an endoperoxide trigger to release a quinone methide dye for subsequent attachment to proximal biological nucleophiles, providing a permanent fluorescent stain at sites of elevated labile iron. IG1-FM imaging reveals that degradation of the major iron storage protein ferritin through ferritinophagy expands the labile iron pool, while activation of nuclear factor-erythroid 2-related factor 2 (NRF2) antioxidant response elements (AREs) depletes it. We further show that lung cancer cells with heightened NRF2 activation, and thus lower basal labile iron, have reduced viability when treated with an iron chelator. By connecting labile iron pools and NRF2-ARE activity to a druggable metal-dependent vulnerability in cancer, this work provides a starting point for broader investigations into the roles of transition metal and antioxidant signaling pathways in health and disease.

3 June 2024 in ACS Applied Materials & Interfaces
Verified
Journal Article
Open access
JAJavier Bonet Aletá
Javier Bonet Aletá
MEMiguel Encinas-Gimenez
Miguel Encinas-Gimenez
MOMiku Oi
Miku Oi
APAidan T. Pezacki
Aidan T. Pezacki
Victor SebastianVictor Sebastian
Victor Sebastian
JSJesus Santamaria
Jesus Santamaria
Copper plays critical roles as a metal active site cofactor and metalloallosteric signal for enzymes involved in cell proliferation and metabolism, making it an attractive target for cancer therapy. In this study, we investigated the efficacy of polydopamine nanoparticles (PDA NPs), classically applied for metal removal from water, as a therapeutic strategy for depleting intracellular labile copper pools in triple-negative breast cancer models through the metal-chelating groups present on the PDA surface. By using the activity-based sensing probe FCP-1, we could track the PDA-induced labile copper depletion while leaving total copper levels unchanged and link it to the selective MDA-MB-231 cell death. Further mechanistic investigations revealed that PDA NPs increased reactive oxygen species (ROS) levels, potentially through the inactivation of superoxide dismutase 1 (SOD1), a copper-dependent antioxidant enzyme. Additionally, PDA NPs were found to interact with the mitochondrial membrane, resulting in an increase in the mitochondrial membrane potential, which may contribute to enhanced ROS production. We employed an in vivo tumor model to validate the therapeutic efficacy of PDA NPs. Remarkably, in the absence of any additional treatment, the presence of PDA NPs alone led to a significant reduction in tumor volume by a factor of 1.66 after 22 days of tumor growth. Our findings highlight the potential of PDA NPs as a promising therapeutic approach for selectively targeting cancer by modulating copper levels and inducing oxidative stress, leading to tumor growth inhibition as shown in these triple-negative breast cancer models.